Subclinical disease activity in systemic lupus erythematosus: Immunoinflammatory markers do not normalize in clinical remission

Journal of Rheumatology

Volumn 30, Issue 10, 2003, Pages 2133-2139

  Wais, Thomas ^a   Fierz, Walter ^b   Stoll, Thomas ^d   Villiger, Peter M ^a,c  

^a UNIVERSITY OF BERN   (Switzerland)

^b Inst Clin Immunol/Microbiol   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d NONE

Author keywords

Adhesion molecules; Bilag; Cytokine antagonists; Cytokines; Disease activity; Systemic lupus erythematosus

Indexed keywords

CELL ADHESION MOLECULE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; HERMES ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 6; NEOPTERIN; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE MARKER; FEMALE; HUMAN; IMMUNOPATHOLOGY; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REMISSION; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; BIOLOGICAL MARKERS; COHORT STUDIES; CYTOKINES; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERCELLULAR ADHESION MOLECULE-1; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; REFERENCE VALUES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; VASCULAR CELL ADHESION MOLECULE-1;

EID: 0141865742     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
2. Hay EM. Systemic lupus erythematosus. Baillieres Clin Rheumatol 1995;9:437-70.
3. Stoll T, Stucki G, Malik J, Pyke S, Isenberg DA. Further validation of the BILAG disease activity index in patients with systemic lupus erythematosus. Ann Rheum Dis 1996;55:756-60.
4. Buchi S, Villiger P, Kauer Y, Klaghofer R, Sensky T, Stoll T. PRISM (Pictorial Representation of Illness and Self Measure) - a novel visual method to assess the global burden of illness in patients with systemic lupus erythematosus. Lupus 2000;9:368-73.
5. Stoll T, Kauer Y, Buchi S, Klaghofer R, Sensky T, Villiger PM. Prediction of depression in systemic lupus erythematosus patients using SF-36 Mental Health scores. Rheumatology 2001;40:695-8.
6. Morrow WJ, Isenberg DA, Parry HF, Snaith ML. C-reactive protein in sera from patients with systemic lupus erythematosus. J Rheumatol 1981;8:599-604.
7. Zein N, Ganuza C, Kushner I. Significance of serum C-reactive protein elevation in patients with systemic lupus erythematosus. Arthritis Rheum 1979;22:7-12.
8. Morrow WJ, Isenberg DA, Todd-Pokropek A, Parry HF, Snaith ML. Useful laboratory measures in the management of systemic lupus erythematosus. QJM 1982;51:125-38.
9. Clough JD, Barna BP, Danao-Camara TC, Chang RK. Serological detection of disease activity in SLE. Clin Biochem 1992;25:201-8.
10. Honig S, Goreciv P, Weissman G. C-reactive protein in systemic lupus erythematosus. Arthritis Rheum 1977;20:1065-70.
11. ter Borg EJ, Horst G, Limburg PC, van Rijswijk MH, Kallenberg CG. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: a prospective longitudinal study. J Rheumatol 1990;17:1642-8.
12. Swaak AJ, Aarden LA, Statius van Eps LW, Feltkamp TE. Anti-dsDNA and complement profiles as prognostic guides in systemic lupus erythematosus. Arthritis Rheum 1979;22:225-35.
13. Isenberg DA, Dudeney C, Williams W, Todd-Pokropek A, Stollar BD. Disease activity in systemic lupus erythematosus related to a range of antibodies binding DNA and synthetic polynucleolides. Ann Rheum Dis 1988;47:717-24.
14. ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CG. Measurement of increases in anti-double stranded DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long-term prospective study. Arthritis Rheum 1990;33:634-43.
15. Villiger PM, Cronin MT, Amenomori T, Wachsman W, Lotz M. IL-6 production by human T lymphocytes. Expression in HTLV-1-infected but not in normal T cells. J Immunol 1991;146:550-9.
16. Robak E, Sysa-Jedrzejowska A, Stepien H, Robak T. Circulating interleukin-6 type cytokines in patients with systemic lupus erythematosus. Eur Cytokine Netw 1997;8:281-6.
17. Peterson E, Robertson AD, Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus 1996;5:571-5.
18. Stuart RA, Littlewood AJ, Maddison PJ, Hall ND. Elevated serum interleukin-6 levels associated with active disease in systemic connective tissue disorders. Clin Exp Rheumatol 1995;13:17-22.
19. Park YB, Lee SK, Kim DS, Lee J, Lee CH, Song CH. Elevated interleukin-10 levels correlated with disease activity in systemic lupus erythematosus. Clin Exp Rheumatol 1998;16:283-8.
20. Scudla V. Horak P, Faltynek L, Pospisil Z, Budikova M, Hermanova Z. The importance of determination of interleukin-10 in the blood of patients with systemic lupus erythematosus. Cas Lek Cesk 1998;137:44-7.
21. Horwitz DA. Gray JD, Behrendsen SC, et al. Decreased production of interleukin-12 and other Th1-type cytokines in patients with recent-onset systemic lupus erythematosus. Arthritis Rheum 1998;41:838-44.
22. Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. I. Excessive production of IL-10 suppresses production of IL-12 by monocytes. Cytokine 1998;10:140-7.
23. Liu TF, Jones BM. Impaired production of IL-12 in systemic lupus erythematosus. II. IL-12 production in vitro is correlated negatively with serum IL-10, positively with serum IFN-gamma and negatively with disease activity in SLE. Cytokine 1998;10:148-53.
24. Turan B, Gallati H, Erdi H, Gurler A, Michel BA, Villiger PM. Systemic levels of the T cell regulatory cytokines IL-10 and IL-12 in Bechcet's disease; soluble TNFR-75 as a biological marker of disease activity. J Rheumatol 1997;24:128-32.
25. Gattorno M, Picco P, Barbano G, et al. Differences in tumor necrosis factor-alpha soluble receptor serum concentrations between patients with Henoch-Schonlein purpura and pediatric systemic lupus erythematosus: pathogenetic implications. J Rheumatol 1998;25:361-5.
26. Gabay C, Cakir N, Moral F, et al. Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity. J Rheumatol 1997;24:303-8.
27. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumor necrosis factor alpha and its soluble receptors parallel clinical disease autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996;35:1067-74.
28. Davas EM, Tsirogianni A, Kappou I, Karamitsos D, Economidou I, Dantis PC. Serum IL-6, TNF alpha, p55srTNF alpha, p75srTNF alpha, srIL-2 alpha levels and disease activity in systemic lupus erythematosus. Clin Rheumatol 1999;18:17-22.
29. Aderka D, Wysenbeek A, Engelmann H, et al. Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus. Arthritis Rheum 1993;36:1111-20.
30. Suzuki H, Takemura H, Kashiwagi H. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity. Arthritis Rheum 1995;38:1055-9.
31. Sturfelt G, Roux-Lombard P, Wollheim FA, Dayer JM. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus. Br J Rheumatol 1997;36:1283-9.
32. Spronk PE, Bootsma H, Huitema MG, Limburg PC, Kallenberg GM. Levels of soluble VCAM-1, soluble ICAM-1 and soluble E-selectin during disease exacerbations in patients with systemic lupus erythematosus; a long term prospective study. Clin Exp Immunol 1994;97:439-44.
33. Skifakis PP. Charalambopoulos D, Vayiopoulos G, Oglesby R, Sfikakis P, Tsokos GC. Increased levels of intercellular adhesion molecule-1 in the serum of patients with systemic lupus erythematosus. Clin Exp Rheumatol 1994;12:5-9.
34. Tulek N, Aydintug O, Ozoran K, et al. Soluble intercellular adhesion molecule-1 in patients with systemic lupus erythematosus. Clin Rheumatol 1996;15:47-50.
35. Caligaris-Cappio F, Bertero MT, Converso M, et al. Circulating levels of soluble CD30, a marker of cells producing Th2-type cytokines, are increased in patients with systemic lupus erythematosus and correlate with disease activity. Clin Exp Rheumatol 1995;13:339-43.
36. Estess P. DeGrendele HC, Pascual V, Siegelmann MH. Functional activation of lymphocyte CD44 in peripheral blood as a marker of autoimmune disease activity. J Clin Invest 1998;102:1173-82.
37. Guo YJ, Liu G, Wang X, et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994;54:422-6.
38. Samsonov MY, Tilz GP, Egorova O, et al. Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus. Lupus 1995;4:29-32.
39. Lim KL, Muir K, Powell RJ. Urine neopterin: a new parameter for serial monitoring of disease activity in patients with systemic lupus erythematosus. Ann Rheum Dis 1994;53:743-8.
40. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
41. Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risk of future myocardial infarction in apparently bealthy men. Lancet 1998;351:88-92.
42. Lahita RG. Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am 2000;26:951-68.
43. Spronk PE, Limburg PC, Kallenberg CG. Serological markers of disease activity in systemic lupus erythematosus. Lupus 1995;4:86-94.
44. Bienvenu J, Coulon L, Doche C, Gutowski MC, Grau GE. Analytical performances of commercial ELISA kits for IL-2, IL-6 and TNF-alpha. A WHO study. Eur Cytokine Netw 1993;4:447-51.
45. Roux Lombard P, Steiner G. Preliminary report on cytokine determination in human synovial fluids: a consensus study of the European Workshop for Rheumatology Research. The Cytokine Consensus Study Group of the European Workshop for Rheumatology Research. Clin Exp Rheumatol 1992;10:515-20.
46. Manzi S, Wasko MC. Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000;59:321-5.